Efficacy and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a meta-analysis with trial sequential analysis of randomized controlled trials by Ji Ren, Jinghe Wang, Yanan Wang, Dongying Yang, Jianming Sheng, Shili Zhu, Yunli Liu, Xiaoqi Li, Wei Liu, Binbin Zhang

Subjects: Get full text

PD-1/PD-L1 inhibitors related adverse events: A bibliometric analysis from 2014 to 2024 by Qingya Song, Zongliang Yu, Wenping Lu, Zhili Zhuo, Lei Chang, Heting Mei, Yongjia Cui, Dongni Zhang

Subjects: Get full text

Efficacy and safety of PD-1/PD-L1 inhibitors in patients with Merkel Cell Carcinoma: a systematic review and Meta-analysis by Francisco Cezar Aquino de Moraes, Michele Kreuz, Isabella Christina Amaral de Lara, Artur de Oliveira Macena Lôbo, Rommel Mario Rodríguez Burbano

Subjects: Get full text

Identification of novel PD-1/PD-L1 small molecule inhibitors: virtual screening, synthesis and in vitro characterisation by Tingting Wu, Hu Cheng, Lijie Sima, Zhongyuan Wang, Weiwei Ouyang, Jianta Wang, Yunlei Hou, Dongsheng Zhao, Weike Liao, Chujiao Hu

Subjects: Get full text

Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer by Cecilia Olsson Ladjevardi, Marcus Skribek, Anthoula Koliadi, Viktoria Rydén, Ali Inan El-Naggar, Evangelos Digkas, Antonios Valachis, Gustav J. Ullenhag

Subjects: Get full text

Combined systemic immune-inflammatory index and prognostic nutritional index predicts the efficacy and prognosis of ES-SCLC patients receiving PD-L1 inhibitors combined with first-... by Yi Ge, Xiaoyu Liu, Yishi Xu, Yanwei Su, Yixin Li, Liping Wang

Subjects: Get full text

The efficacy of neoadjuvant immunotherapy in gastric cancer, adenocarcinoma of the esophagogastric junction, and esophageal cancer: a meta-analysis by Mengyi Qian, Yingying Fang, Zhiyi Xiang, Yueming Zhang, Hujie Zhan, Xiaotong Chen, Yihang Chen, Tinghui Xu

Subjects: “…PD-1/PD-L1 inhibitors…”
Get full text

Comparative efficacy of anthracycline-free and anthracycline-containing neoadjuvant chemoimmunotherapy regimens for triple-negative breast cancer by Yuhan Wei, Qiao Li, Hongnan Mo, Yalong Qi, Hewei Ge, Xiaoying Sun, Ying Fan, Pin Zhang, Jiayu Wang, Yang Luo, Jing Wang, Fei Ma

Subjects: “…PD-1/PD-L1 Inhibitors…”
Get full text

Updated Bayesian network meta-analysis on the efficacy and safety of PD−1 versus PD−L1 inhibitors in first−line treatment with chemotherapy for extensive−stage small-cell lung canc... by Ke Wang, Ke Wang, Chuangjie Zheng, Chuangjie Zheng, Xinrong Chen, Xinrong Chen, Penghui Lin, Mengge Lin, Cuizhen Chen, Linzhu Zhai

Subjects: Get full text

Immune-related adverse events with PD-1/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients by Ting Yan, Minghui Long, Chaoyi Liu, Jiwen Zhang, Jiwen Zhang, Xingyu Wei, Xingyu Wei, Fei Li, Fei Li, Dehua Liao

Subjects: “…PD-1/PD-L1 inhibitors…”
Get full text

The clinical value of local consolidative therapy for oligo-residual disease in PD-1/PD-L1 inhibitors-treated non-small cell lung cancer by Yuqi Su, Pan Luo, Ling Ni, Jianbin Hu, Jie Weng, Erdong Shen, Qiang Zhou, Tao Chen, Jiwen Xiao, Jia Xiao, Wangti Xie, Rong Shan, Xiang Yao, Fang Wen

Subjects: Get full text

A network comparison on efficacy and safety profiling of PD-1/PD-L1 inhibitors in first-line treatment of advanced non-small cell lung cancer by Jie Fu, Jie Fu, Yi-Dan Yan, Xu Wan, Xiao-Fan Sun, Xiao-Fan Sun, Xiu-Mei Ma, Ying-Jie Su

Subjects: Get full text

Progression patterns in patients with advanced hepatocellular carcinoma treated with local therapy, targeted drugs, and PD-1/PD-L1 inhibitors by Yanan Zhao, Di Wu, Quanjun Yao, Hang Yuan, Hongtao Hu, Hailiang Li

Subjects: Get full text

Case report: Low-dose interleukin-2: a treatment of bullous pemphigoid with predominantly perifollicular blistering caused by PD-1/PD-L1 inhibitor by Yingyue Zhang, Yingyue Zhang, Xianwei Cao, Xianwei Cao, Jianbo Tong, Jianbo Tong

Subjects: Get full text

Risk of immune‐related pneumonitis for PD1/PD‐L1 inhibitors: Systematic review and network meta‐analysis by Yafang Huang, Haiyu Fan, Ning Li, Juan Du

Subjects: Get full text

Results from the IMpower132 China cohort: Atezolizumab plus platinum‐based chemotherapy in advanced non‐small cell lung cancer by Shun Lu, Jian Fang, Ziping Wang, Yun Fan, Yunpeng Liu, Jianxing He, Jianying Zhou, Jie Hu, Jinjing Xia, Wenxin Liu, Jane Shi, Jing Yi, Lejie Cao

Subjects: Get full text

Overcoming the resistance of hepatocellular carcinoma to PD-1/PD-L1 inhibitor and the resultant immunosuppression by CD38 siRNA-loaded extracellular vesicles by Jun Deng, Hui Ke

Subjects: Get full text

Effectiveness and safety of pembrolizumab, nivolumab, and atezolizumab as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: an indirect comparison by Wei Chen, Wei Chen, Soichiro Yoshida, Noriyoshi Miura, Shohei Fukuda, Hiroshi Fukushima, Yuma Waseda, Hajime Tanaka, Yasuhisa Fujii

Subjects: Get full text

A computational chemistry-based approach to optimizing PD-1/PD-L1 inhibitors by Meijuan Zhai, Shiliang Ji, Haoran Hu, Yongjie Wu, Yi Shi, Ruifang Zhu, Yiguo Jiang, Yang Yang

Subjects: Get full text

Immune Checkpoint Blockade Combined with AbnobaViscum^® Therapy Is Linked to Improved Survival in Advanced or Metastatic Non-Small-Cell Lung Cancer Patients: A Registry S... by Friedemann Schad, Anja Thronicke, Ralf-Dieter Hofheinz, Reinhild Klein, Patricia Grabowski, Shiao Li Oei, Hannah Wüstefeld, Christian Grah

Subjects: Get full text